Decreased serum apolipoprotein AII/AI ratio in systemic amyloidosis.
OBJECTIVE
To investigate if serum apolipoprotein A-I and A-II (apoAI and apAII) concentrations change in subjects with systemic amyloidosis secondary to underlying disorders.


METHODS
Serum concentrations of apoAI and apoAII were measured in 21 multiple myeloma patients, including eight with amyloidosis; 95 rheumatoid arthritis patients, including 45 with amyloidosis; and 73 haemodialysis patients, including 32 with amyloidosis.


RESULTS
ApoAII values tended to be reduced in subjects with amyloidosis in each group, but could not effectively distinguish amyloidosis. However, apoAII/AI ratios were significantly lower in subjects with amyloidosis in all groups. The ratio of 0.2 had diagnostic sensitivity and specificity for amyloidosis; 50% and 100%, respectively, in multiple myeloma; 80% and 78%, respectively, in rheumatoid arthritis; and 46% and 90%, respectively, in patients requiring long term haemodialysis.


CONCLUSIONS
The apoAII/AI ratio can be a useful biochemical marker of suspect amyloidosis in patients with underlying diseases, especially those with rheumatoid arthritis.
Department of Clinical Pathology, Jichi Medical School, Tochigi, Japan.
T
T
Yamada
T
T
Ozawa
F
F
Gejyo
Y
Y
Okuda
K
K
Takasugi
O
O
Hotta
Y
Y
Itoh
D000686:Amyloidosis / Q000097:blood* / Q000150:complications; D016632:Apolipoprotein A-I / Q000032:analysis*; D016633:Apolipoprotein A-II / Q000032:analysis*; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000150:complications; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000150:complications; D006435:Renal Dialysis; D012680:Sensitivity and Specificity
D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D015415:Biomarkers